PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes

FDA approval of trial testing generic vaccine announced at ADA Scientific Sessions

2015-06-07
(Press-News.org) A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients, was announced today at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory and principal investigator of the study.

The five-year trial will investigate whether repeat BCG vaccination can clinically improve type 1 diabetes in adults between 18 and 60 years of age who have small but still detectable levels of insulin secretion from the pancreas. Faustman's research team was the first group to document reversal of advanced type 1 diabetes in mice and subsequently completed a successful phase I human clinical trial of BCG vaccination. She announced the FDA approval to launch the phase II trial during her ADA presentation, "Low Levels of C-Peptide Have Clinical Significance for Established Type 1 Diabetes."

"We have learned a lot since the early studies in mice - not just about how BCG works but also about its potential therapeutic benefits, similar to what are being seen in trials against other autoimmune diseases," says Faustman. "We are so grateful to all of the donors, large and small, who have made this trial possible - especially the Iacocca Foundation, which has believed in us and has been a supporter since our early days. Our goal is to complete enrollment and also to raise the remaining funds needed for the trial by the end of this year."

A generic drug with over 90 years of clinical use and safety data, BCG is currently approved by the FDA for vaccination against tuberculosis and for the treatment of bladder cancer. The vaccine is known to elevate levels of the immune modulator tumor necrosis factor (TNF), which Faustman's team previously showed can temporarily eliminate in both humans and mice the abnormal white blood cells responsible for autoimmune type 1 diabetes. Increased TNF levels also stimulated production of protective regulatory T cells.

In the phase I clinical trial, which was published in the August 8, 2012, issue of PLOS Medicine, two injections of BCG spaced four weeks apart led to temporary elimination of diabetes-causing T cells and provided evidence of a small, transient return of insulin secretion. The phase II clinical study will include more frequent dosing over a longer time period to determine the potential of repeat BCG vaccination to ameliorate the autoimmune state and improve clinical parameters such as HbA1c, a marker of average blood sugar control.

In the new trial, which will be double blinded and conducted at MGH, 150 adults with long-term type 1 diabetes will be randomized to receive two injections four weeks apart of either BCG or placebo and then a single injection annually for the next four years. Patients will be closely monitored over the five-year trial period. The primary outcome measure will be improved results on the HbA1c blood test, which have been shown to prevent complications.

"In the phase I clinical trial we demonstrated a statistically significant response to BCG, but our goal in phase II is to create a lasting therapeutic response," says Faustman, an associate professor of Medicine at Harvard Medical School. "We will be working again with people who have had type 1 diabetes for many years. This is not a prevention trial; instead, we are trying to create a regimen that will treat even advanced disease. In addition to our phase I trial, we took guidance from the BCG clinical trials that are underway globally for other autoimmune diseases such as multiple sclerosis."

Lee Iacocca, founder of the Iacocca Foundation, says, "My family and I have been fortunate to be part of this research for many years. It is incredibly exciting to be talking about curing people, not mice. I made a promise to my late wife to find a cure for type 1 diabetes. Now my family and I look forward to the continued progress and are proud to support this effort to get closer to that goal." The Iacocca Foundation provided major funding for the phase I trial and has taken a leadership role in funding the phase II trial.

More than $19 million has been raised out of a total of $25 million needed to conduct the phase II study over the next five years. Additional information about the clinical trial, including information for potential participants and financial supporters, is available at http://www.faustmanlab.org or by emailing DiabetesTrial@partners.org. Details on the trial and enrollment also are available at: https://clinicaltrials.gov/ct2/show/NCT02081326.

INFORMATION:

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $760 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.



ELSE PRESS RELEASES FROM THIS DATE:

50 years of diabetes research and treatment

2015-06-06
BOSTON (June 6, 2015) - From how people test their glucose levels to how long they can expect to live, almost everything has changed over the past 50 years for Americans with diabetes. A special symposium held at the American Diabetes Association's 75th Scientific Sessions features a look back at what physicians and researchers have learned and how the lives of patients have changed during the past five decades. "There are things that have happened over the past 50 years that clearly make life a lot better for people," said Fred Whitehouse, MD, Division Head Emeritus ...

Novel genetic mutations may arise during early embryonic development

2015-06-06
Until now, de novo genetic mutations, alterations in a gene found for the first time in one family member, were believed to be mainly the result of new mutations in the sperm or eggs (germline) of one of the parents and passed on to their child. Researchers from The Netherlands have now succeeded in determining that at least 6.5% of de novo mutations occur during the development of the child (post-zygotic) rather than from the germline of a parent. The research is published today in the American Journal of Human Genetics*. Christian Gilissen, PhD, Assistant Professor ...

Discovery of new genetic mutation in aortic disease allows better diagnosis

2015-06-06
Glasgow, United Kingdom: Thoracic aortic aneurysm and dissection (TAAD), an enlargement or tearing of the walls of the aorta in the chest, is, together with abdominal aortic aneurysms, responsible for about 2% of all deaths in Western countries. The aorta is the largest artery in the body, and carries blood from the heart. About one out of every five patients with TAAD has a family member with the same disorder, therefore indicating a genetic cause. However, the relevant genetic mutations discovered so far only explain about 30% of all cases. Through the study of a large ...

Noninvasive prenatal testing: Effective, safe, preferred by parents

2015-06-06
Glasgow, United Kingdom: Non-invasive prenatal testing (NIPT) for Down's syndrome is feasible, acceptable to parents, and could be introduced into the National Health Service (NHS), UK researchers say. The results of a National Institute for Health Research (NIHR) study carried out by the first NHS laboratory to provide NIPT testing will be reported to the annual conference of the European Society of Human Genetics today (Saturday). Presenting her team's findings, Professor Lyn Chitty, from the UCL Institute of Child Health and Great Ormond Street Hospital, London, UK, ...

First national study of noninvasive prenatal testing shows it works

2015-06-06
Glasgow, United Kingdom: Results from a national study of non-invasive prenatal testing (NIPT) in women at high risk of having a baby with Down's syndrome will be presented at the annual conference of the European Society of Human Genetics today (Saturday). The Netherlands is the first country in the world to include NIPT in a government supported, healthcare-funded trisomy syndrome screening programme. In many other countries, such screening is offered by commercial companies and without governmental guidance, so studying the accuracy of the programme and its acceptability ...

Noninvasive prenatal fetal testing can detect early stage cancer in mothers

2015-06-06
Glasgow, United Kingdom: Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods. Now, for the first time, researchers have found another advantage of NIPT; it can detect maternal cancers at an early stage, before symptoms appear. The study, to be presented to the annual conference of the European Society of Human Genetics today (Saturday), is ...

Rabbit virus improves bone marrow transplants, kills some cancer cells

2015-06-05
University of Florida Health researchers have discovered that a rabbit virus can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants. For patients with blood cancers such as leukemia and multiple myeloma, a bone marrow transplant can be both curative and perilous. It replenishes marrow lost to disease or chemotherapy but raises the risk that newly transplanted white blood cells will attack the recipient's body. Now researchers say the myxoma virus, found in rabbits, can do double ...

Research reveals key interaction that opens the channel into the cell's nucleus

Research reveals key interaction that opens the channel into the cells nucleus
2015-06-05
Cells have devised many structures for transporting molecular cargo across their protective borders, but the nuclear pore complex, with its flower-like, eight-fold symmetry, stands out. Monstrously large by cellular standards, as well as versatile, this elaborate portal controls access to and exit from the headquarters of the cell, the nucleus. In research published June 4 in Cell, Rockefeller University scientists have uncovered crucial steps in the dynamic dance that dilates and constricts the nuclear pore complex -- the latest advance in their ongoing efforts to tease ...

NASA-NOAA's Suomi NPP satellite gets colorful look at Hurricane Blanca

NASA-NOAAs Suomi NPP satellite gets colorful look at Hurricane Blanca
2015-06-05
NASA-NOAA's Suomi NPP satellite flew over Hurricane Blanca in the Eastern Pacific Ocean and gathered infrared data on the storm that was false-colored to show locations of the strongest thunderstorms within the storm. The Visible Infrared Imaging Radiometer Suite or VIIRS instrument aboard the satellite gathered infrared data of the storm that was made into an image at the University of Wisconsin-Madison. The image was false-colored to show temperature. Coldest cloud top temperatures indicate higher, stronger, thunderstorms within a tropical cyclone. Those are typically ...

Fruit fly genetics reveal pesticide resistance and insight into cancer

Fruit fly genetics reveal pesticide resistance and insight into cancer
2015-06-05
For being so small, fruit flies have had a large impact on genetic research. Thomas Werner, an assistant professor of biological sciences at Michigan Technological University, has bridged the miniscule and the massive in an effort to better understand the mechanisms behind several unique features of fruit fly genes. Over the past week, several studies that Werner co-authored have been published in PLoS ONE, the Proceedings of the National Academy of Sciences, and Nature Education. All are linked by Drosophila--a genus of fruit flies--and the insights that fruit fly genetics ...

LAST 30 PRESS RELEASES:

Vitamin E succinate controls tumor growth and enhances immunotherapy effects

University of Tennessee physicist named Cottrell Scholar

Simple, quick test can predict fall risk in older adults six months in advance

Mass General Brigham researchers awarded ARPA-H funding to enhance health outcomes in rural America

Semaglutide shows promise in reducing cravings for alcohol, heavy drinking

Epidural steroid injections for chronic back pain: An AAN systematic review

More sunshine as a baby linked to less disease activity for children with MS

Study finds more barriers to genetic testing for Black children than white children

Removal of parental consent requirement reduces gestational duration at abortion for minors

Dating is not broken, but the trajectories of relationships have changed

Global study identifies markers for the five clinical stages of Parkinson’s disease

Bacterial cellulose promotes plant tissue regeneration

Biohybrid hand gestures with human muscles

Diabetes can drive the evolution of antibiotic resistance

ChatGPT has the potential to improve psychotherapeutic processes

Prioritise vaccine boosters for vulnerable immunocompromised patients and prevent emergence of new COVID variants, say scientists

California's most economically and culturally important species among those most vulnerable to projected climate change

Scientists develop novel self-healing electronic skin for health monitoring

Models show intensifying wildfires in a warming world due to changes in vegetation and humidity; only a minor role for lightning

Unraveling the complex role of climate in dengue dynamics

INSEAD celebrates five years of impact in North America during its second Americas Conference 2025

MAGE-4 promotes tumor progression by halting antitumor responses

Economically, culturally important marine species vulnerable to changing climate, new study shows

Tennessee professor receives SAEA Emerging Scholar Award

Sea turtles’ secret GPS: researchers uncover how sea turtles learn locations using Earth's magnetic field

Mayo Clinic researchers and surgeons test virtual reality to calm presurgery jitters

Mothers with incarcerated children shoulder emotional and financial burdens

Adults can learn absolute pitch: new research challenges long-held musical belief

Loneliness and social isolation linked to increased risk of non-alcoholic fatty liver disease, study finds

Exotic observations with neutrons at the ILL

[Press-News.org] Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes
FDA approval of trial testing generic vaccine announced at ADA Scientific Sessions